Adam Perzin, MD
Urology · Mount Laurel, NJNPI 1104879501
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 39.4% of the total.
Across 97 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$2K
- Bayer$957
- Johnson & Johnson$304
- Neotract Inc.$221
- Procept Biorobotics Corporation$169
- Teleflex LLC$149
- plus $874 from 24 others
Across 71 payments — averaging $3081.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dendreon Pharmaceuticals LLC$122K
- Ferring Pharmaceuticals AS$26K
- Ferring International Pharmascience Center US$26K
- GSK$22K
- Janssen Research & Development, LLC$22K
- Sumitomo Pharma America, Inc.$2K
What the payments were for
- Consulting fees$2,56258%
- Food & beverage$1,75240%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 4 | $1,741 |
| Bayer | 6 | $957 |
| Johnson & Johnson | 22 | $304 |
| Neotract Inc. | 9 | $221 |
| Procept Biorobotics Corporation | 1 | $169 |
| Teleflex LLC | 4 | $149 |
| Astellas Pharma US Inc | 9 | $147 |
| Medtronic(2 entities) | 3 | $145 |
| Ferring Pharmaceuticals Inc. | 6 | $84 |
| Pfizer | 6 | $79 |
| Antares Pharma, Inc. | 4 | $57 |
| Axonics, Inc. | 3 | $57 |
| Olympus America Inc. | 1 | $29 |
| Urovant Sciences Inc | 2 | $29 |
| AstraZeneca | 2 | $28 |
| 180 Medical, Inc. | 1 | $25 |
| Palette Life Sciences, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Amgen | 1 | $14 |
| Sanofi | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Myovant Sciences Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Metuchen Pharmaceuticals | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Photocure Inc | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$1,690
- Nubeqa$872
- Xofigo$872
- AquaBeam Robotic System$169
- UroLift$111
How this compares
$4,414 in reported general payments places this provider in the 70th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 115 | $1,551,318 |
| ErleadaApalutamide | 31 | $444,071 |
| Abiraterone Acetate | 190 | $402,814 |
| NubeqaDarolutamide | 30 | $356,165 |
| MyrbetriqMirabegron | 97 | $103,796 |
| GemtesaVibegron | 43 | $36,037 |
| Tamsulosin Hcl | 780 | $12,634 |
| Finasteride | 393 | $6,019 |
| Silodosin | 58 | $5,171 |
| Oxybutynin Chloride ErOxybutynin Chloride | 212 | $5,155 |
| Testosterone | 25 | $4,005 |
| Trospium Chloride ErTrospium Chloride | 12 | $3,494 |
| NitrofurantoinNitrofurantoin Macrocrystal | 76 | $3,329 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,292 |
| Trospium Chloride | 45 | $2,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $147 | $1,655,114212 claims |
| Johnson & JohnsonErleada | $304 | $444,07131 claims |
| BayerNubeqa | $957 | $356,16530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 401 urology providers in New Jersey.
Other urology in Mount Laurel
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.